Antibody response from China Zhifei’s COVID shot weaker against Omicron
BEIJING (Reuters) – China’s Anhui Zhifei Longcom Biopharmaceutical said on Monday a small laboratory test showed its COVID-19 vaccine could trigger antibodies against the Omicron variant though the response was weaker than against an older variant of the virus. The unit of Chongqing Zhifei Biological Products is the first Chinese vaccine developer to announce early …
Antibody response from China Zhifei’s COVID shot weaker against Omicron Read More »